Skip to main content
Fig. 2 | BMC Pulmonary Medicine

Fig. 2

From: Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial

Fig. 2

Change from test-day baseline (SE) in FEV1 AUC0–6 and peak FEV1 after 4 weeks. Mean (adjusted) change and post-hoc analysis of mean ratio of change from test-day baseline (SE) in FEV1 AUC0–6 and peak FEV1 after 4 weeks using the mixed-effect model repeated measures (MMRM). a Mean (adjusted) change from test-day baseline in FEV1 AUC 0–6 (ml) (95 % CI of the difference: (0.058, 0.112) p <0.0001); b Mean ratio of change from test-day baseline in FEV1 AUC0-6 (%) (95 % CI of the difference: (0.032, 0.061) p <0.0001); c Mean (adjusted) change from test-day baseline in peak FEV1 (ml) (95 % CI of the difference: (0.047, 0.107) p <0.0001); d Mean ratio of change from test-day baseline in peak FEV1 (%) (95 % CI of the difference: (0.027, 0.060) p <0.0001)

Back to article page